APR has a strategic development relationship with Cato Research, a leading contract research and development organization (CRO) with over 300 employees worldwide. Cato Research is the core portfolio company of Cato BioVentures, a life science venture capital firm and APR's largest shareholder. Due to its strategic affiliation with Cato Research and its extensive expertise working with novel pharmaceutical products, APR has unique strategic access to a wide range of CRO services to support its development of APR 102.  Accordingly, APR expects its development activities to remain financially disciplined and heavily based on flexible, real-time strategic outsourcing to Cato Research and other vendors to avoid the significant fixed-cost financial and management burden typically associated with building and maintaining a large, fully integrated product development infrastructure. Additionally, APRs strategic access to Cato Research's pharmaceutical industry client base provides APR with unique access to a network of prospective pharmaceutical partners with interest in treatments for chronic pain, such as APR 102.